Skip to main content

Table 1 EC50 and maximal plateau from TDCC assays [%] with CEACAM5-positive tumor cell lines

From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

 

NILK-2301

EC50 nM

Max plateau

SK-CO-1

0.06 ± 0.07

43.52 ± 7.26

SNU-C1

0.02 ± 0.01

24.99 ± 12.47

H508

0.15 ± 0.17

14.1 ± 7.56

SW1116

0.033 ± 0.03

38.03 ± 6.71

LS-174 T

0.059 ± 0.09

26.67 ± 9.09

MKN-45

0.02 ± 0.03

27.87 ± 6.31

SNU-16

0.08 ± 0.11

20.92 ± 13.59

H2122

0.008 ± 0.005

25.5 ± 3.7

  1. Readout using LDH release after incubation for 48 h